Hympavzi (marstacimab-hncq subcutaneous injection – Pfizer) — Cigna

Hemophilia B without Factor IX inhibitors

Initial criteria

Patient is age ≥ 12 years; AND
Patient is using Hympavzi for routine prophylaxis to prevent or reduce the frequency of bleeding episodes; AND
Patient has moderately severe to severe hemophilia B as evidenced by a baseline (without Factor IX replacement therapy) Factor IX level of ≤ 2%; AND
Patient meets ONE of the following (a or b): a) Factor IX inhibitor titer testing has been performed within the past 30 days AND patient does not have a positive test for Factor IX inhibitors of ≥ 1.0 Bethesda units/mL; OR b) Patient has not received Factor IX therapy in the past; AND
According to the prescriber, prophylactic use of Factor IX products will be discontinued (Note: use for breakthrough bleeding is permitted); AND
Medication is prescribed by or in consultation with a hemophilia specialist

Patient is using Hympavzi for routine prophylaxis to prevent or reduce the frequency of bleeding episodes; AND
According to the prescriber, prophylactic use of Factor IX products will not occur while receiving Hympavzi (Note: use for breakthrough bleeding is permitted); AND
Medication is prescribed by or in consultation with a hemophilia specialist; AND
According to the prescriber, patient experienced a beneficial response to therapy (e.g., reduction in bleeding events, severity, number requiring treatment, or spontaneous bleeds)

1 year